Last week’s hot topic on ALS was an article titled Biohaven’s ALS Drug Candidate BHV-0223 Receives Positive FDA Feedback written by Magdalena Kegel.
The article is focused on the recently announcement that Portage Biotech and Biohaven Pharmaceuticals have received positive feedback from the U.S. Food and Drug Administration (FDA) on their Pre-Investigational New Drug Application (PIND) interaction regarding Biohaven’s investigative drug BHV-0223, intended for treatment of amyotrophic lateral sclerosis (ALS).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?